635
Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.
 children with increased-risk ALL or stage III and IV lymphoblastic lymphoma: Subject; increased-risk ALL or stage III and IV lymphoblastic lymphoma: Subject.Disorder; children: Subject.Age; HD IV MTX and intrathecal injections of MTX: Treatment; CNS relapse: Treatment.Disorder; MTX: Treatment.Drug; MTX: Treatment.Drug; intrathecal injections: Treatment.Route; HD IV: Treatment.Route; MTX: Combination.Drug; MTX: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 children with increased-risk ALL or stage III and IV lymphoblastic lymphoma: Subject; increased-risk ALL or stage III and IV lymphoblastic lymphoma: Subject.Disorder; children: Subject.Age; HD IV MTX and intrathecal injections of MTX: Treatment; CNS relapse: Treatment.Disorder; MTX: Treatment.Drug; MTX: Treatment.Drug; intrathecal injections: Treatment.Route; HD IV: Treatment.Route; MTX: Combination.Drug; MTX: Combination.Drug